Cryogenic Cables Market Size, Share, Growth, and Industry Analysis, By Type (Single-Core Cryogenic Cables, Multi-Core Cryogenic Cables), By Application (Residential, Commercial, Industrial), Regional Insights and Forecast From 2026 To 2035

Corneal Transplant Market Overview

The global corneal transplant market size is anticipated to be valued at USD 485.95 Million in 2026, with a projected growth to USD 762.12 Million by 2035 at a CAGR of 4.8% during the forecast from 2026 to 2035.

The global corneal transplant market is expanding as ophthalmic centers adopt advanced keratoplasty techniques, donor tissue preservation systems, regenerative therapies, and precision surgical technologies. Corneal transplantation remains an established treatment for severe corneal opacity, endothelial dysfunction, keratoconus, corneal scarring, and other vision-threatening disorders. In the United States, domestic keratoplasty procedures reached 52,396 in 2025, demonstrating sustained procedural demand. Endothelial procedures are increasingly important, with DMEK becoming the leading domestic keratoplasty procedure at 19,042 cases in 2025. The corneal transplant market is also moving toward pre-cut tissue, minimally invasive techniques, artificial corneas, cell-based regeneration, improved preservation media, and technologies designed to address donor-tissue shortages.

The United States remains a highly developed corneal transplant market because of established eye-bank infrastructure, specialist ophthalmology centers, advanced reimbursement systems, and high adoption of endothelial keratoplasty. U.S. eye banks reported 143,081 total ocular tissue recoveries from 72,143 donors during 2025, supporting a substantial supply network for transplantation and research. Domestic keratoplasty procedures increased to 52,396 during 2025, while DMEK accounted for 19,042 procedures and DSAEK accounted for 15,953 procedures. The U.S. market is also experiencing increasing interest in regenerative approaches, artificial corneal technologies, improved tissue preservation, and donor-independent treatment platforms for corneal endothelial disease.

Key Findings

• By Type: Endothelial Keratoplasty leads the market with over 60% share, while Descemet Stripping Automated Endothelial Keratoplasty advances fastest at a 4.8% CAGR.
• By Application: Hospitals lead with over 65% market share, supported by advanced operating infrastructure and comprehensive postoperative care capabilities.
• By Solution Category: Tissue-engineered corneal substitutes represent the fastest-growing solution category, supported by regenerative technologies and donor shortages across emerging markets.
• By End User: Specialty eye clinics represent approximately 25% market share, supported by specialized surgeons, outpatient capabilities, and efficient postoperative management services.
• By Geography: North America leads with over 35% share, while Asia-Pacific represents the fastest-growing region, driven by expanding transplant infrastructure..

Corneal Transplant Market Latest Trends

The corneal transplant market is undergoing a significant transition from conventional full-thickness transplantation toward selective tissue replacement and regenerative approaches. Endothelial keratoplasty has become increasingly important because it replaces dysfunctional endothelial tissue while preserving healthier corneal layers. U.S. data demonstrate this shift clearly, with DMEK recording 19,042 procedures in 2025 compared with 14,802 penetrating keratoplasty procedures. DSAEK represented another 15,953 procedures, confirming strong demand for posterior lamellar techniques.

Pre-cut donor tissues are gaining importance because they can reduce intraoperative preparation requirements and support consistent surgical workflows. Eye banks are increasingly offering tissues specifically prepared for DMEK and DSAEK procedures. Advanced preservation media are also supporting longer and safer tissue handling, improving flexibility for hospitals and eye clinics.

Regenerative medicine is becoming another major trend. Cell-based therapies seek to restore endothelial function without conventional donor-graft transplantation. Aurion Biotech advanced AURN001 into a phase three clinical study in 2026 for corneal edema associated with endothelial dysfunction, illustrating the movement toward cultured cell therapy. Lineage Cell Therapeutics is also developing COR1 as an off-the-shelf allogeneic corneal endothelial cell program.

Artificial corneal technologies are receiving greater attention because donor shortages remain a major limitation. Improvements in biomaterials, tissue engineering, laser-cut graft preparation, and cell expansion are creating additional opportunities for the corneal transplant market. These developments are increasing competition between traditional donor-tissue platforms and emerging regenerative technologies.

Corneal Transplant Market Dynamics

DRIVER

"Rising prevalence of corneal disorders and increasing adoption of advanced keratoplasty techniques."

The growing prevalence of corneal disorders is a central driver of the corneal transplant market. Fuchs endothelial corneal dystrophy, keratoconus, corneal scarring, infectious keratitis, pseudophakic corneal decompensation, and traumatic corneal damage create continuing demand for transplantation. Aging populations are particularly important because endothelial dysfunction and postoperative corneal decompensation become more prevalent with age. Advanced procedures such as DMEK and DSAEK are gaining preference because they allow selective replacement of damaged corneal layers rather than complete replacement of the cornea. In the United States, DMEK reached 19,042 procedures during 2025, making it the most frequently performed domestic keratoplasty procedure. Increasing surgeon training, better tissue preparation, improved surgical instruments, and enhanced postoperative management are further supporting adoption. The growth of specialized corneal centers and expanding eye-bank networks is also increasing access to transplantation. These factors collectively support sustained demand for donor tissues, pre-cut grafts, preservation solutions, surgical instruments, and regenerative corneal technologies.

RESTRAINT

"Persistent donor cornea shortages and uneven eye-bank infrastructure limit access to transplantation."

The shortage of suitable donor corneas remains one of the most important restraints affecting the corneal transplant market. Global demand substantially exceeds the availability of transplantable tissue, creating long waiting periods and restricting treatment access in many countries. Eye-bank infrastructure is unevenly distributed, particularly across low-resource healthcare systems where donor recruitment, tissue retrieval, laboratory testing, preservation, and transportation capabilities may be limited. Tissue transportation can also create logistical challenges because endothelial cell viability and tissue quality must be carefully maintained before transplantation. Regulatory requirements surrounding human tissue further increase operational complexity. Hospitals also require specialized ophthalmic surgeons capable of performing advanced endothelial procedures, which can limit adoption outside major medical centers. High procedural costs, limited insurance coverage in some countries, and inadequate awareness of eye donation can further restrict supply. These barriers encourage development of artificial corneas, regenerative cell therapies, improved tissue preservation, and technologies capable of increasing utilization from individual donor tissues.

OPPORTUNITY

"Expansion of regenerative cell therapy and donor-independent corneal treatment technologies."

Regenerative medicine represents one of the strongest opportunities in the corneal transplant market. Conventional transplantation depends on donor corneas, while cell-based approaches seek to restore damaged endothelial function using cultured cells. This approach could potentially expand treatment capacity because a single donor-derived cell source may support treatment for substantially more patients than a conventional graft. Aurion Biotech advanced AURN001 into a phase three study during 2026, targeting corneal edema associated with endothelial dysfunction and positioning cultured cell therapy as an alternative to donor-tissue transplantation. Lineage Cell Therapeutics is also developing COR1 using allogeneic corneal endothelial cells with an off-the-shelf formulation. Tissue engineering creates another opportunity through artificial corneas, bioengineered grafts, and patient-specific tissue solutions. Advanced laser cutting can improve graft customization for keratoconus and other irregular corneal conditions. Investments in automated tissue preparation, digital eye-bank systems, endothelial cell assessment, and improved preservation media can further increase the value of the corneal transplant market.

CHALLENGE

"Balancing tissue quality, surgical complexity, regulatory requirements, and equitable access to advanced transplantation."

The corneal transplant market faces significant challenges related to tissue quality, procedural expertise, patient selection, regulatory compliance, and healthcare accessibility. Advanced endothelial procedures require specialized surgical skills, precise tissue preparation, and careful postoperative management. DMEK is particularly dependent on delicate donor tissue handling, which creates operational requirements for eye banks and surgical centers. Tissue quality must be evaluated through endothelial cell assessment, sterility testing, preservation monitoring, and appropriate transportation. Regulatory requirements for donor tissues and emerging regenerative therapies can also lengthen product development timelines. Developing markets face additional challenges because eye-bank infrastructure and specialist ophthalmologists may be concentrated in large cities. Patient awareness of eye donation remains another challenge because donor availability directly affects transplant capacity. Artificial corneas and cell therapies may eventually reduce dependence on donor tissue, but these technologies require clinical validation, manufacturing scalability, regulatory approval, and long-term safety assessment. Ensuring affordability while introducing advanced technologies will remain important for sustainable market development.

Corneal Transplant Market Segmentation

By Type

• Penetrating Keratoplasty: Penetrating keratoplasty accounted for an estimated 34% of the global corneal transplant market by procedure volume. It remains an established option for advanced corneal scarring, severe keratoconus, infectious damage, traumatic injury, and conditions affecting multiple corneal layers. U.S. domestic data recorded 14,802 penetrating keratoplasty procedures during 2025, demonstrating continued clinical importance despite growing adoption of lamellar approaches. Penetrating keratoplasty requires replacement of the full corneal thickness and therefore depends strongly on high-quality donor tissue. The procedure remains particularly relevant when selective layer replacement cannot adequately restore corneal transparency or structural integrity. Demand is supported by established surgical training, standardized instruments, and extensive clinical experience. However, longer visual recovery and greater graft-related management requirements encourage clinicians to consider selective procedures when clinically appropriate.
• Endothelial Keratoplasty: Endothelial keratoplasty represented an estimated 38% share of the global corneal transplant market, making it the largest procedure category. The technique has gained importance because it selectively replaces dysfunctional endothelial tissue while retaining healthier anterior corneal structures. It is widely used for endothelial disorders including Fuchs endothelial corneal dystrophy and pseudophakic corneal decompensation. The clinical preference for endothelial techniques is supported by improved visual recovery, smaller surgical incisions, and reduced dependence on full-thickness graft replacement. In Germany, DMEK became the predominant keratoplasty procedure after 2016, illustrating the broader transition toward endothelial surgery. Continued surgeon training and improvements in tissue preparation are expected to support endothelial keratoplasty demand. Pre-cut donor tissue, specialized injectors, graft preparation equipment, and postoperative monitoring technologies further strengthen this segment.
• Descemet Stripping Automated Endothelial Keratoplasty: DSAEK represented an estimated 16% share of the global corneal transplant market. The technique remains widely used because it provides selective endothelial replacement while offering established surgical handling characteristics. In the United States, 15,953 DSAEK procedures were recorded during 2025, demonstrating substantial clinical utilization. DSAEK can be particularly attractive where surgeons seek a standardized endothelial graft procedure with predictable tissue handling. Although DMEK has gained greater prominence in several mature markets, DSAEK continues to serve patients with endothelial dysfunction and remains part of the established ophthalmic surgical portfolio. Eye banks increasingly provide pre-cut tissue to simplify surgical preparation and improve procedural efficiency. Continued demand is supported by experienced surgeons, established equipment, tissue availability, and clinical familiarity.
• Corneal Limbal Stem Cell Transplant: Corneal limbal stem cell transplant accounted for an estimated 7% market share. The procedure addresses severe ocular surface disorders involving limbal stem cell deficiency, which can result from chemical injury, thermal injury, chronic inflammation, or other forms of ocular surface damage. The segment differs from conventional corneal transplantation because treatment focuses on restoring the regenerative capacity of the corneal epithelium. Advances in cell expansion, tissue engineering, and regenerative medicine are increasing commercial interest in this area. Specialized laboratories and ophthalmology centers are developing improved approaches for harvesting, expanding, preserving, and delivering limbal cells. Growth opportunities are particularly strong where regenerative medicine infrastructure is developing. Greater clinical awareness and improvements in cell-based manufacturing can increase the role of limbal stem cell transplantation within the broader corneal transplant market.
• Others: Other procedures accounted for an estimated 5% share of the global corneal transplant market. This category includes specialized grafting procedures, deep anterior lamellar approaches, therapeutic transplantation, artificial corneal implantation, and emerging tissue-engineered solutions. The segment is strategically important because innovation frequently begins with specialized procedures before broader clinical adoption. Artificial corneal systems can provide alternatives for patients with severe corneal damage or repeated graft failure. Tissue engineering and patient-specific graft preparation are also expanding the potential applications of this segment. Improvements in biomaterials, cell culture, laser processing, and surgical delivery systems are supporting innovation. The others category therefore provides opportunities for companies developing differentiated technologies that address conditions inadequately served by conventional donor corneal transplantation.

By Application

• Hospital: Hospitals represented an estimated 47% share of the global corneal transplant market by application. Hospitals maintain operating rooms, ophthalmology departments, tissue-handling facilities, anesthesia capabilities, and postoperative monitoring systems required for complex transplantation. Large hospitals also have access to multidisciplinary teams that can manage patients with systemic conditions, traumatic injuries, infections, or complex corneal disease. The hospital segment benefits from established procurement systems and relationships with eye banks. Academic hospitals additionally support surgeon training, clinical trials, regenerative medicine research, and development of new transplantation techniques. The increasing adoption of DMEK and other advanced procedures supports demand for specialized surgical equipment and pre-cut tissue. Hospitals will remain important because complicated corneal cases often require comprehensive clinical infrastructure.
• Eye Clinics: Eye clinics represented an estimated 43% share of the corneal transplant market. Specialized eye clinics are increasingly important because many corneal procedures can be performed in focused ophthalmology environments with dedicated surgeons and optimized patient pathways. Eye clinics typically emphasize high procedural efficiency, specialized diagnostic equipment, and shorter treatment workflows. The growing adoption of endothelial keratoplasty supports this segment because DMEK and DSAEK can often be delivered through specialized ophthalmic surgical centers. Eye clinics also provide postoperative monitoring, endothelial assessment, visual acuity evaluation, and management of graft-related complications. Expansion of private ophthalmology networks in developing economies can further strengthen this segment. Increasing investments in advanced microscopes, tissue preparation systems, and minimally invasive surgical instruments support the competitive positioning of specialized eye clinics.
• Others: Other applications accounted for an estimated 10% market share and include academic centers, specialty research institutions, ambulatory surgical facilities, charitable eye-care organizations, and specialized tissue programs. These organizations contribute to corneal transplantation through research, training, tissue processing, patient outreach, and clinical innovation. Academic centers are particularly important for testing regenerative therapies, artificial corneas, tissue-engineering platforms, and new endothelial transplantation techniques. Charitable eye-care networks support transplantation among underserved populations and help improve access where conventional healthcare financing is limited. Eye-bank partnerships also strengthen this segment by coordinating tissue retrieval, preservation, quality assessment, and distribution. Continued development of community eye-care infrastructure can increase the contribution of non-hospital and non-clinic organizations to the global corneal transplant market.

Corneal Transplant Market Regional Outlook

• North America

North America accounted for an estimated 36% share of the global corneal transplant market and maintained the strongest regional position because of sophisticated eye-bank networks, high procedure volumes, advanced ophthalmology infrastructure, and rapid adoption of endothelial keratoplasty. The United States recorded 52,396 domestic keratoplasty procedures in 2025, demonstrating the scale of the regional market. DMEK represented 19,042 U.S. procedures, while DSAEK represented 15,953 procedures during the same year. U.S. eye banks also reported 143,081 ocular tissue recoveries from 72,143 donors, supporting strong tissue availability and processing capacity. Canada contributes through specialized ophthalmology centers, donor programs, and tissue distribution systems. North American companies and research institutions are also heavily involved in regenerative medicine, artificial corneal development, tissue preservation, and endothelial cell therapy. Strong reimbursement systems, clinical research capabilities, and specialist training further support market leadership.

• Europe

Europe represented an estimated 27% share of the global corneal transplant market and remains a major center for keratoplasty innovation. European countries maintain established eye banks, tissue-processing standards, ophthalmology registries, and specialist surgical networks. Germany is particularly significant because DMEK has been the predominant keratoplasty procedure since 2016. European clinical research increasingly focuses on endothelial transplantation, graft survival, tissue engineering, and regenerative treatment approaches. The region also benefits from cross-border tissue movement, specialized corneal centers, and structured healthcare systems. Demand is supported by aging populations and the prevalence of Fuchs endothelial corneal dystrophy, keratoconus, and postoperative corneal decompensation. European eye banks are increasingly offering pre-cut tissues and specialized graft formats for DMEK and DSAEK. Innovation in preservation media, tissue evaluation, and surgical preparation strengthens the regional competitive environment.

• Germany Corneal Transplant Market Insights

Germany accounted for an estimated 9% of the global corneal transplant market and remains one of Europe’s most advanced keratoplasty countries. Reported keratoplasties increased to 8,998 procedures in 2021, demonstrating substantial surgical capacity. DMEK became the leading procedure, with 5,812 procedures recorded in 2021. Fuchs endothelial corneal dystrophy represented 43% of the principal indications, while pseudophakic corneal decompensation represented 12%. Germany’s specialist ophthalmology departments, clinical registries, university hospitals, and experienced corneal surgeons support advanced transplantation. The market is increasingly oriented toward selective endothelial replacement rather than conventional full-thickness surgery. Strong clinical research activity also supports innovation in graft preparation, endothelial cell preservation, postoperative monitoring, and regenerative approaches.

• United Kingdom Corneal Transplant Market Insights

The United Kingdom represented an estimated 6% share of the global corneal transplant market and maintains a well-developed corneal transplantation ecosystem. National eye-banking capabilities, specialist ophthalmology services, and organized donor programs support tissue availability. The United Kingdom has also developed substantial expertise in endothelial keratoplasty and lamellar transplantation. Specialist centers are increasingly adopting procedures that replace only diseased corneal layers, supporting demand for pre-cut tissues and advanced surgical instruments. Research institutions contribute to clinical studies involving corneal graft survival, tissue preservation, cell therapy, and artificial corneal technologies. The market benefits from centralized healthcare planning and specialist referral pathways, although donor availability and regional differences in access remain important considerations.

• Asia

Asia represented an estimated 25% share of the global corneal transplant market and offers substantial opportunities because of its large population, significant burden of corneal blindness, and expanding ophthalmic infrastructure. India, China, Japan, South Korea, and other Asian markets are increasing investments in eye banking, specialist surgical training, tissue processing, and corneal transplantation. The LV Prasad Eye Institute network reported 11,910 corneas harvested and 7,555 corneas distributed during 2025, demonstrating the scale of organized eye banking in India. Asia is also becoming an important region for artificial corneal research, regenerative medicine, and affordable transplantation technologies. Japan has strong adoption of endothelial procedures, while China is investing in domestic ophthalmic technologies and tissue infrastructure. Uneven access remains a challenge, but expanding eye banks, charitable programs, and specialist centers are improving treatment availability.

• Japan Corneal Transplant Market Insights

Japan accounted for an estimated 5% share of the global corneal transplant market and has a highly specialized ophthalmology sector. A national survey recorded 4,943 corneal transplantation cases, with DSAEK representing 41.3% and penetrating keratoplasty representing 37.1%. These figures demonstrate strong utilization of both endothelial and full-thickness procedures. Japan’s aging population supports continued demand for treatment of endothelial disorders and postoperative corneal dysfunction. Specialist hospitals have developed extensive expertise in DSAEK, DMEK, and other lamellar procedures. The market is also influenced by donor availability, tissue import requirements, and the need for efficient eye-bank coordination. Clinical research into endothelial cell preservation and advanced transplantation techniques supports continued innovation.

• China Corneal Transplant Market Insights

China represented an estimated 8% share of the global corneal transplant market and is an important emerging market because of its large patient population and expanding ophthalmology infrastructure. The country has increased investment in eye banks, corneal centers, specialist training, and domestic ophthalmic technologies. Artificial corneal development is also receiving attention, including approval of the Miok Keratoprosthesis, which uses non-biological materials. Demand is supported by keratoconus, infectious corneal disease, trauma, and other causes of corneal opacity. Greater availability of specialized surgeons and improved tissue-processing infrastructure can increase transplantation capacity. Domestic innovation may also reduce dependence on imported technologies and strengthen China’s role in the Asia-Pacific corneal transplant market.

• Middle East & Africa

Middle East and Africa accounted for an estimated 12% share of the global corneal transplant market and represent an underserved but strategically important region. Limited donor availability, uneven eye-bank infrastructure, specialist shortages, and transportation challenges restrict access in several countries. However, international partnerships, charitable ophthalmology programs, and regional eye banks are improving transplantation capacity. Healthcare investments in Saudi Arabia, the United Arab Emirates, South Africa, and other markets are supporting advanced ophthalmic services. Eye donation awareness programs can strengthen tissue availability, while specialist training can expand access to endothelial keratoplasty. The region also presents opportunities for affordable tissue preservation technologies, portable diagnostic systems, artificial corneas, and regenerative therapies. Expansion of cross-border tissue networks and cooperation with established eye banks can further improve treatment availability.

Key Industry Players

The competitive landscape includes tissue-processing companies, ophthalmic technology developers, eye-bank organizations, regenerative medicine companies, and medical-device manufacturers. Established players compete through tissue quality, preservation technologies, surgical compatibility, distribution networks, regulatory capabilities, and clinical partnerships. Emerging companies are increasingly targeting donor-independent solutions through artificial corneas and cell-based therapies. Partnerships with hospitals, surgeons, research institutions, and eye banks are important for clinical adoption. Companies are also investing in pre-cut graft technologies, advanced preservation media, endothelial cell solutions, tissue engineering, and patient-specific corneal treatments. Competitive positioning increasingly depends on the ability to improve graft availability, simplify procedures, support surgeon efficiency, and address donor-tissue shortages.

List of Top Corneal Transplant Companies

• CryoLife, Inc.
• Exactech, Inc.
• Köhler GmbH
• Lifeline Scientific
• LIFECELL CORPORATION
• Medtronic

List of Top Two Companies Market Share

• CryoLife, Inc.: Estimated 18% market share, supported by established tissue preservation, processing capabilities, clinical relationships, and strong ophthalmic market positioning.
• Medtronic: Estimated 14% market share, supported by extensive medical-device capabilities, surgical technologies, global distribution, and ophthalmology-related development activities.

Investment Analysis And Opportunities

Investment opportunities in the corneal transplant market are increasingly concentrated around regenerative medicine, tissue preservation, artificial corneas, automated graft preparation, and donor-independent treatments. Endothelial disease represents a particularly attractive area because global unmet demand remains substantial. The U.S. market alone recorded 52,396 domestic keratoplasty procedures during 2025, creating a significant installed clinical base for innovative technologies. Investors are also evaluating eye-bank modernization, digital tissue tracking, pre-cut graft preparation, cell expansion platforms, and advanced preservation solutions. Asia provides opportunities through eye-bank infrastructure expansion and affordable surgical technologies. Companies capable of improving donor utilization, extending tissue usability, simplifying surgery, or reducing dependence on donor tissue are positioned to attract strategic investment.

New Product Development

New product development in the corneal transplant market is increasingly focused on regenerative cell therapy, artificial corneas, pre-cut grafts, advanced storage media, and patient-specific tissue preparation. CorneaGen has developed corneal tissue addition for keratoconus using patient-specific laser-cut tissue inlays, demonstrating the potential of customized tissue solutions. Aurion Biotech is advancing AURN001 as a cultured cell therapy for corneal endothelial disease, while Lineage Cell Therapeutics is developing COR1 as an off-the-shelf allogeneic endothelial cell platform. Advanced storage solutions are also supporting tissue viability, with modern preservation systems designed to maintain donor corneas for up to 14 days under appropriate conditions. These innovations are expanding treatment options beyond conventional transplantation.

Corneal Transplant Five Recent Developments (2025–2026)

• ·         April 2026 — Aurion Biotech — Aurion advances AURN001 into phase three development for corneal endothelial disease treatment.

Aurion Biotech initiated patient dosing in the ASTRA phase three study, advancing cultured endothelial cell therapy to potentially restore corneal clarity while reducing dependence on donor graft transplantation.

• ·         July 2026 — Lineage Cell Therapeutics — Lineage advances COR1 for donor-independent endothelial disease treatment.

• ·         July 2025 — CorneaGen — CorneaGen expands patient-specific tissue solutions for keratoconus treatment.

• ·         January 2025 — Alchimia — Alchimia expands specialized corneal preservation solutions for modern eye-bank workflows.

Alchimia strengthened its eye-banking portfolio with synthetic storage media, corneal preservation technologies, and specialized transport solutions designed to maintain donor tissue quality before transplantation.

• ·         June 2025 — Eye Bank Coordination And Research Centre — EBCRC expands advanced pre-cut corneal tissue services for lamellar transplantation.

EBCRC continued providing pre-cut corneal tissues for DSAEK and DMEK procedures, supporting specialized eye-bank processing, efficient surgical preparation, and expanded access to advanced transplantation.

Corneal Transplant Market Report Coverage

The corneal transplant market report covers procedure types, applications, regional performance, competitive positioning, market dynamics, technology development, investment opportunities, and recent industry developments. The analysis evaluates penetrating keratoplasty, endothelial keratoplasty, DSAEK, corneal limbal stem cell transplantation, and other emerging procedures. Application coverage includes hospitals, eye clinics, and other specialized healthcare settings. Regional analysis includes North America, Europe, Germany, the United Kingdom, Asia, Japan, China, and Middle East and Africa. The report also examines donor tissue availability, eye-bank infrastructure, regenerative medicine, artificial corneas, tissue preservation, pre-cut grafts, and cell-based therapies. U.S. domestic keratoplasty procedures reached 52,396 during 2025, providing an important benchmark for market activity.